home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Tumor Treatment Blocks Blood Vessels

  February, 3 2004 11:26
your information resource in human molecular genetics
Tumors rely on vascular endothelial growth factor (VEGF) to stimulate new blood vessels critical for their survival. In the February issue of Nature Medicine, Christopher Willett and colleagues highlight the effects of bevacizumab (Avastin), an antibody that inactivates VEGF, on blood vessels in rectal tumors.

The authors tested six patients with rectal cancer in a phase 1 clinical trial of the drug. They found that, in addition to decreasing interstitial fluid pressure and blood flow to the tumor, bevacizumab also reduces the density of tumor blood vessels. The results suggest that the antibody may also cause tumor vessels to function more normally.
The antivascular effects of bevacizumab, which has shown success in a clinical trial for colorectal cancer, might enhance the effects of standard chemotherapy agents, the researchers suggest.

Author contact:

Christopher G. Willett
Massachusetts General Hospital
Boston, MA
Tel: +1 617 724 1548
E-mail: cwillett@partners.org

Also available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.